Generics: India’s Copycats That Saved the World

Generics: India’s Copycats That Saved the World

There’s a wrong notion doing the rounds: “Generics are bad, substandard, third-rate pills.” Absolute rubbish.

Here’s the truth bomb: Every so-called ‘branded’ Indian medicine is a branded generic. Cipla, Sun, Ranbaxy (now Sun), Torrent—none of them have their own billion-dollar “research molecule.” They are all copycats. And you know what? Thank God for these copycats—because without them, the world couldn’t afford medicines.

In fact, only one original, homegrown R&D molecule exists in India: Lipaglyn (Saroglitazar) from Zydus. That’s it. One candle in a forest of generics.

Now, about the quality drama. Our pharma plants are GMP- and WHO-certified, FDA-audited, and EU-approved. The same pills Indians suspect as “low-grade” are shipped by the ton to America, Europe, and Africa. If they’re good enough for the U.S. FDA, why suddenly “bad” in Bengaluru or Bhopal?

The real circus isn’t quality—it’s pricing politics. Inside pharma companies, it’s always trade price vs. institutional price. A salesman will sell his higher-priced brand by whispering that the cheaper institutional one is “second quality.” Joke’s on the customer—it’s the same pill with a different invoice. Divide and rule, straight out of the corporate playbook.

And then comes America, waving its big stick. A 54% tariff on Indian generics? That’s not policy—it’s economic suicide dressed as patriotism. Indian pharma supplies 40% of U.S. generics. Kill us, and you kill your own affordability.

So let’s stop pretending. Indian generics are not “third class.” They are world-class copycats—the very reason millions of patients live longer, healthier, and cheaper.

India didn’t just learn it; we earned it.